Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Doxycycline attenuates breast cancer related inflammation by decreasing plasma lysophosphatidate concentrations and inhibiting NF-κB activation

Fig. 1

Doxycycline delayed breast tumor growth, decreased plasma LPA concentration, inhibited F4/80+ macrophage infiltration and blood vessel formation in the tumor. a. Tumor volume from day 5 to day 15 post inoculation of 4T1 cells. BALB/c mice were treated with doxycycline (Dox) at 50 mg/kg/day by i.p. injection. Control mice were given saline by i.p. injection. n = 6 for each group, * p < 0.05 relative to control. b. The difference in tumor weight. n = 6 for each group, ** p < 0.01 relative to control. c. Image of the tumors from control and Dox treated mice. d. Plasma LPA concentration of the mice with tumor. n = 6 for each group, * p < 0.05 relative to control. e. Plasma autotoxin (ATX) activity of control and Dox treated mice. f. F4/80+ macrophage numbers per field detected by IHC in tumors from control and Dox treated mice. * p < 0.05 relative to control. g. CD31+ blood vessel numbers per field detected by IHC in tumors from control and Dox treated mice. * p < 0.05 relative to control. These were quantified by examining 5 different fields from each tumor and by using 6 mice per group. h. Representative images of IHC staining for F4/80+ macrophages and CD31+ blood vessels in tumors from control and Dox treated mice. Scale bar = 100 μm. Results are means ± SEM. Results were analyzed by a Student’s t-test

Back to article page